Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study Journal Article


Authors: Farley, J.; Fuchiuji, S.; Darcy, K. M.; Tian, C.; Hoskins, W. J.; McGuire, W. P.; Hanjani, P.; Warshal, D.; Greer, B. E.; Belinson, J.; Birrer, M. J.
Article Title: Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study
Abstract: Objective(s): The Gynecologic Oncology Group (GOG) examined the association between ERBB2 amplification and clinical covariates, tumor response, disease status post-chemotherapy, progression-free survival (PFS), and overall survival (OS) in epithelial ovarian cancer (EOC). Methods: Women with suboptimally-resected, advanced stage EOC who participated in GOG-111, a multi-center randomized phase III trial of cyclophosphamide + cisplatin versus paclitaxel + cisplatin, and provided a tumor block through the companion protocol GOG-9404 were eligible. ERBB2 amplification was examined using fluorescence in situ hybridization (FISH) with probes for ERBB2 and the centromere of chromosome 17 (CEP17). Results: ERBB2 amplification, defined as > 2 copies of ERBB2/CEP17, was a rare event in EOC with 7% (9/133) of women exhibiting between 2.2 and 33.7 copies of ERBB2/CEP17, and was not associated with patient age, race, GOG performance status, stage, cell type, grade, measurable disease status, volume of ascites, tumor response or disease status post-chemotherapy. Women with > 2 verses ≤ 2 copies of ERBB2/CEP17 did not have a reduced risk of disease progression (hazard ratio [HR] = 0.56; 95% confidence interval [CI] = 0.27-1.16; p = 0.120) or death (HR = 0.57; 95% CI = 0.26-1.23; p = 0.152), and ERBB2 amplification was not an independent prognostic factor for PFS or OS. ERBB2 amplification, defined as > 4 copies of ERBB2/nuclei, was observed in 9% (12/133) of women with levels ranging from 4.2 to 49.2 copies of ERBB2/nuclei, and was associated with older age and volume of ascites, but not with the other clinical covariates or outcome. Conclusion(s): ERBB2 amplification is a rare event and has no predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy. © 2009.
Keywords: adult; cancer survival; controlled study; aged; disease-free survival; middle aged; young adult; major clinical study; clinical trial; drug tolerability; cisplatin; advanced cancer; cancer growth; drug efficacy; paclitaxel; cancer staging; ovarian neoplasms; in situ hybridization, fluorescence; controlled clinical trial; multiple cycle treatment; ovary cancer; gene amplification; randomized controlled trial; antineoplastic combined chemotherapy protocols; epidermal growth factor receptor 2; randomized controlled trials as topic; cyclophosphamide; carcinogenesis; ovary; disease progression; phase 3 clinical trial; fish; clinical trials, phase ii as topic; erbb2; genes, erbb-2
Journal Title: Gynecologic Oncology
Volume: 113
Issue: 3
ISSN: 0090-8258
Publisher: Elsevier Inc.  
Date Published: 2009-06-01
Start Page: 341
End Page: 347
Language: English
DOI: 10.1016/j.ygyno.2009.02.009
PUBMED: 19272639
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 2" - "Export Date: 30 November 2010" - "CODEN: GYNOA" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. William Hoskins
    193 Hoskins